Celltrion Files Phase 4 IND with FDA to Support 240 mg High-Dose Zymfentra Regimen in US
Celltrion has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for a Phase 4 clinical trial of Zymfentra...
Search results for "U.S. market"
The "Complete Protein" Myth: How Animal Meat Triggers Cancer, Hypertension, and Diabetes
Animal protein is widely celebrated as a "complete protein" because it contains all essential amino acids.
SK Plasma Launches High-Dose Revolpag 75 mg to Simplify Thrombocytopenia Regimens and Cut Costs
SK Plasma announced on Sept. 1 that it has begun distributing Revolpag Tablets 75 mg in South Korea, expanding its...
Zymfentra U.S. Sales Surge 176% as Celltrion’s Remsima Franchise Eyes 1 Trillion Won Annual Revenue
Biopharmaceutical company Celltrion announced on Aug. 27 that combined first-half sales of its subcutaneous infliximab...
Celltrion Files for South Korean Approval of Keytruda Biosimilar CT-P51
Celltrion announced on August 24 that it has submitted a marketing authorization application to South Korea’s Ministry...
“Miracle” Eye Supplements Can’t Cure Glaucoma or Cataracts, Ophthalmologists Warn
“Lowers intraocular pressure to improve glaucoma and cataracts. ” “Prevents macular degeneration.
Moderna’s Landmark mRNA Cancer Vaccine Phase 3 Success Spotlights Korean Biotech Ties
Positive late-stage clinical results for a personalized messenger RNA cancer vaccine developed by Moderna and Merck are...
Roen Surgical’s Kidney Stone Robot Zamenix Secures US FDA Clearance
Zamenix, a kidney stone surgery robot developed by medical robotics company Roen Surgical, has received Class II...
Global Asset Managers Expand Holdings in South Korean Pharma and Biotech
Major institutional asset managers are steadily increasing their equity stakes in South Korean pharmaceutical and...
Faithful to Supplements, but Health Declines? Why Breakfast Produce Matters Most
On rushed mornings, taking vitamins, omega-3s, probiotics, or protein powders has become a standard routine for many...